Clarice Dow

Clarice Dow is a private investigator and Keith Perkins’s partner, serving as a careful intermediary between the investigation into the Nightingale account and the inquiry into Jack Harkness’s business affairs. Friendly but guarded, she combines a watchful manner with detailed knowledge of Harkness’s corporate history; her account lays out both what investigators know and the large financial questions they cannot yet answer.

Identity and Investigative Manner

Blake first sees Clarice during a meeting with Keith Perkins. She describes Clarice as a Black woman probably in her forties, with big, watchful eyes and a soft voice. Clarice seems friendly but cautious, giving nothing away. Blake, who has arrived intent on appearing sharp and savvy, recognizes that the investigators are assessing her as carefully as she is assessing them.

The room reinforces the guarded atmosphere of the meeting: the blinds are down, and several computers and laptops are connected to extra hard drives by trailing cables. When Don Challenor asks whether they are worried about surveillance, the question fits the circumstances, but the scene does not establish that Clarice or Keith has a particular surveillance system in place. Blake guesses their partnership is purely professional; this is her impression, not information Clarice confirms.

Clarice defines the limits of the investigators’ approach when she warns Blake about Amos French. She says that she and Keith are investigators who dig up what they legally can and may cut a few corners, but are basically respectable. French, she stresses, comes from a different area of business and is someone Blake should not get involved with. The warning gives Clarice a practical role in the encounter: she is not merely protecting the information her side holds, but also distinguishing their methods from French’s.

The Exchange over the Nightingale Account

Clarice and Keith regard the operator of the Nightingale account as a person of interest because that person connects a web of suspect dealings. They do not immediately disclose what they have uncovered. Instead, Clarice offers to share more if Blake can identify Luscinia, the account’s operator. The account matters to Blake and Don for a separate reason: money from it has been paying for Holly Walsh’s medication, and an earlier visitor who questioned those payments had not appeared to know anything about Jane Glasson.

Don proposes an exchange: he and Blake will provide what they know about the person they believe to be Luscinia without identifying her, while Keith and Clarice will outline their findings on Harkness. Clarice insists on straightforward answers to straightforward questions and reminds Blake that she has already accepted that arrangement. Blake does not deny it. Don then frames the division of knowledge: he and Blake know more about Harkness’s early life in Cornwall, while the investigators know more about his later life and business career. Clarice supplies the business history that fills that gap.

Clarice’s Account of Harkness

Clarice identifies Harkness as John William Harkness, known as Jack, born on February 29, 1956. He attended Truro School and St John’s College, Cambridge, on scholarships and earned a first-class degree in Archaeology and Anthropology. Between 1978 and 1981 he was largely off the grid. He then appeared in Switzerland as personal assistant to Lenore Furgler, who had inherited control of Furgler Gesellschaft, a medium-sized pharmaceutical company based in Basel. During the 1980s he gained a seat on its board, with responsibility for company strategy, despite the Furgler family’s apparent distrust of him.

Clarice says that Harkness married Mona Jackson, the daughter of a wealthy builder, and that the couple had no children; a later magazine interview with Mona discussed the tragedy of miscarriage. They divided their time between Basel, London, Monte Carlo, and Cornwall. In 1995, as Lenore was ailing, she sold the company to Harkness. The price was neither especially high nor negligible, and investigators could not establish where he got the money. Clarice relays rumours that he borrowed it from Vladimir Drishkov, a Russian oligarch whose mining corporation was described as corruptly acquired. Drishkov was shot dead by unidentified assassins a few months later. Whatever the truth about the financing, Harkness took control, and the company became Harkness Pharmaceuticals.

Under Harkness, the company expanded. He established a research laboratory in Locarno, where Filippo Crosetti developed beauty products, culminating in Elixtris, an anti-ageing cream released in 2009. Clarice links the product’s success to the company’s rise and describes its partnership with Quintagler Industries, a US conglomerate, to fund acquisitions that eliminated competitors in North America, Europe, and Asia. The resulting prosperity makes the alleged diversion of funds a central puzzle rather than an obvious necessity.

Allegations, Unknowns, and Narrative Role

When Blake asks why a highly profitable company would need to steal from partners or resort to bribery, Clarice and Keith acknowledge that Harkness is already extremely wealthy. Clarice explains that one possible motive—pathological greed—does not persuade Keith, who sees Harkness as subtle and calculating. The investigators also point to a pattern of financial arrangements: Harkness chose Swiss pharmaceuticals, moved the company headquarters from Basel to Zug while production remained centred in Basel, and channelled much of his personal salary through Liechtenstein. Clarice’s account presents these arrangements as evidence of careful tax planning, not proof of the alleged theft.

The most serious allegations come from Quintagler: over several years, Harkness is said to have diverted funds to subsidiaries of shell companies ultimately owned by him, which were also alleged to have supplied money for bribes to doctors. Clarice emphasizes the uncertainty in the case. The bribes account for only a fraction of the sums supposedly taken; the shell companies are based in tax havens with limited accounting and disclosure requirements; and investigators do not know what happened to the rest. The Nightingale account is an exception, opened in London and comparatively small. Even after Clarice’s detailed briefing, the larger question remains unresolved: if Harkness took billions, what did he use them for?

Clarice’s contribution therefore expands the inquiry without prematurely solving it. Her expertise supplies dates, business relationships, and the architecture of the allegations, while her insistence on reciprocal disclosure makes information itself a bargaining instrument. The contrast between a lucrative pharmaceutical empire and unexplained transfers sharpens the mystery: the known evidence supports suspicion, but the ultimate purpose of the missing money remains beyond the investigators’ reach.